Discounted Cash Flow
Pacific Biosciences of California, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $90.7m | $-74.4m | $-76.1m | -82.0% | — |
| 2017 | $93.5m (3.0%) | $-92.2m (-24.0%) | $-78.0m (-2.4%) | -98.6% (-20.3%) | — |
| 2018 | $78.6m (-15.9%) | $-102.6m (-11.3%) | $-68.3m (12.4%) | -130.4% (-32.3%) | $-0.76 |
| 2019 | $90.9m (15.6%) | $-84.1m (18.0%) | $-81.1m (-18.8%) | -92.6% (29.0%) | $-0.55 (27.6%) |
| 2020 | $78.9m (-13.2%) | $29.4m (134.9%) | $18.5m (122.8%) | 37.3% (140.3%) | $0.18 (132.7%) |
| 2021 | $130.5m (65.4%) | $-181.2m (-716.3%) | $-117.1m (-734.3%) | -138.9% (-472.6%) | $-0.89 (-594.4%) |
| 2022 | $128.3m (-1.7%) | $-314.2m (-73.4%) | $-280.0m (-139.1%) | -244.9% (-76.4%) | $-1.40 (-57.3%) |
| 2023 | $200.5m (56.3%) | $-306.7m (2.4%) | $-268.0m (4.3%) | -153.0% (37.5%) | $-1.21 (13.6%) |
| 2024 | $154.0m (-23.2%) | $-309.9m (-1.0%) | $-212.2m (20.8%) | -201.2% (-31.5%) | $-1.13 (6.6%) |
| 2025 | $160.0m (3.9%) | $-546.4m (-76.3%) | $-113.9m (46.3%) | -341.5% (-69.7%) | $-1.82 (-61.1%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.